In vitro and ex vivo antioxidant activities of labetalol on rabbit neutrophil respiratory burst

Objective: Labetalol is a non-selective beta blocker which is used for the treatment of hypertension. Its role in controlling the hemodynamic response to tracheal intubation is established. This comparative controlled study was carried out to verify its effects on time to onset of action of rocuronium in comparison to esmolol. Methods:We randomized patients into two groups. Group A receiving injection labetalol 0.25 mg/kg diluted to 10 ml with 0.9% saline and Group B receiving 0.5 mg/kg of esmolol in 10 ml 0.9% saline before surgery. The time to onset of action of rocuronium, systolic blood pressure, and heart rate were recorded. The adverse reactions were observed in the post-operative period.Results: A total of 60 patients were randomized into two groups. At the time of intubation, the systolic blood pressure and heart rate were similar between the two groups. The onset of action of rocuronium was decreased significantly in the labetalol group. Conclusion:Labetalol attenuates the hemodynamic response to tracheal intubation both during intubation. It also slightly decreases the time to onset of action of rocuronium.

show abstract

“…Labetalol also has a unique antioxidant property [20,21]. This may also help to decrease the stress response during surgery.…”

Section: Discussionmentioning

confidence: 99%

Effect of Labetalol and Esmolol on Onset of Action of Rocuronium: A Prospective Double-Blinded Randomized Controlled Trial

Acharya

Mishra

Rath

et al. 2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…The differential effect of the various antihypertensive medications on eNOS expression, both in the absence and presence of TNF‐α and in comparison to each other, may thus be a consequence of their individual mechanisms of action and how this action may intersect with the conflicting pathways of TNF‐α regulation of eNOS mRNA. Labetalol, for example, has been shown to inhibit superoxide production and thus may modulate the effect of TNF‐α induced NADPH oxidase activity.…”

Section: Discussionmentioning

confidence: 99%

Antihypertensive methyldopa, labetalol, hydralazine, and clonidine reversed tumour necrosis factor‐α inhibited endothelial nitric oxide synthase expression in endothelial‐trophoblast cellular networks

Bobek

Makris

et al. 2017

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Medications used to control hypertension in pregnancy also improve trophoblast and endothelial cellular interaction in vitro. Tumour necrosis factor-α (TNF-α) inhibits trophoblast and endothelial cellular interactions and simultaneously decreases endothelial nitric oxide synthase (eNOS) expression. This study investigated whether antihypertensive medications improved these cellular interactions by modulating eNOS and inducible nitric oxide synthase (iNOS) expression. Human uterine myometrial microvascular endothelial cells (UtMVECs) were pre-incubated with (or without) low dose TNF-α (0.5 ng/mL) or TNF-α plus soluble fms-like tyrosine kinase-1 (sFlt-1) (100 ng/mL). The endothelial cells were cultured on Matrigel. After endothelial cellular networks appeared, trophoblast derived HTR-8/SVneo cells were co-cultured in the presence of clinically relevant doses of methyldopa, labetalol, hydralazine or clonidine for 24 hours. Cells were retrieved from the Matrigel to extract mRNA and eNOS and iNOS expression were examined by quantitative PCR. Methyldopa, labetalol, hydralazine and clonidine reversed the inhibitory effect of TNF-α on eNOS mRNA expression. After pre-incubating endothelial cells with TNF-α and sFlt-1, all the medications except methyldopa lost their effect on eNOS mRNA expression. In the absence of TNF-α, antihypertensive medications did not change eNOS expression. The mRNA expression of iNOS was not affected by TNF-α or any medications. This study shows that selected antihypertensive medications used in the treatment of hypertension in pregnancy increase eNOS expression in vitro when induced by the inflammatory TNF-α. The anti-angiogenic molecule sFlt-1 may antagonise the potential benefit of these medications by interfering with the NOS pathway.

show abstract

“…Labetalol inhibited production of reactive oxygen species (ROS) by neutrophils and reduced the risk of lipid peroxidation, compared with no such effects seen with conventional -blockade during in vitro and ex vivo studies [41,42]. Data are lacking on the effects of labetalol on vascular cell proliferation.…”

Section: Antioxidant and Antiproliferative Actionsmentioning

confidence: 97%

The vasodilatory beta-blockers

Pedersen¹,

Cockcroft

2007

Current Science Inc

121

102

View full text Add to dashboard Cite

Although well established in treating hypertension and cardiovascular (CV) disease, clinical trial data suggest that beta-blockers (eg, atenolol) may be less effective than other antihypertensive classes in reducing stroke and CV mortality despite similar blood pressure (BP) reductions. One possible explanation is that atenolol is less effective in reducing central aortic pressure. Newer vasodilating beta-blockers may prove more effective in reducing central pressure and cardiovascular events. Carvedilol and labetalol appear to cause vasodilation through alpha(1)-receptor blockade; nebivolol induces endothelium-dependent vasodilation by stimulating nitric oxide bioactivity. Their favorable hemodynamic profile includes reduction of peripheral vascular resistance (PVR) while maintaining or improving cardiac output (CO), stroke volume, and left ventricular function, whereas nonvasodilating beta-blockers tend to raise PVR and reduce CO and left ventricular function. Compared with conventional beta-blockers, vasodilating beta-blockers have beneficial hemodynamic effects including decreased pressure wave reflection from the periphery, leading to decreases in central aortic blood pressure. Larger trials are needed to determine whether reduced central pressure will translate into improved CV outcomes compared with nonvasodilating beta-blockers.

show abstract

In vitro and ex vivo antioxidant activities of labetalol on rabbit neutrophil respiratory burst

Cited by 10 publications

References 22 publications

Effect of Labetalol and Esmolol on Onset of Action of Rocuronium: A Prospective Double-Blinded Randomized Controlled Trial

Effect of Labetalol and Esmolol on Onset of Action of Rocuronium: A Prospective Double-Blinded Randomized Controlled Trial

Antihypertensive methyldopa, labetalol, hydralazine, and clonidine reversed tumour necrosis factor‐α inhibited endothelial nitric oxide synthase expression in endothelial‐trophoblast cellular networks

The vasodilatory beta-blockers

Contact Info

Product

Resources

About